Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%
Year: 2019
Type: article
Abstract: Traditional management of diabetes mellitus has focused on glycemic control, beginning with lifestyle changes, followed by metformin, and then other classes of antiglycemic agents.1 Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular (CV) events, including CV death, myocardial infarction (MI) and heart failure, and slow progression of renal dysfunction, including prevention of end-stage kidney disease (ESKD).2-3 Because initial clinical trials included mostly patients with baseline HbA1c >7%, current guidelines have recommended this class as add-on therapy for patients whose HbA1c is not at goal, typically ≥7%.1 We hypothesized that there would be similar benefits on CV and renal endpoints regardless of baseline HbA1c, including those with HbA1c <7%.
Source: Circulation
Authors: Christopher P. Cannon, Vlado Perkovic, Rajiv Agarwal, James Baldassarre, George Bakris, David M. Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J.L. Heerspink, Meg J. Jardine, Adeera Levin, Jing-Wei Li, Bruce Neal, Carol Pollock, David C. Wheeler, Hong Zhang, Bernard Zinman, Kenneth W. Mahaffey
Institutions: Brigham and Women's Hospital, Baim Institute for Clinical Research, Royal North Shore Hospital, UNSW Sydney, The George Institute for Global Health, Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Janssen Research & Development (United States), University of Chicago, University of Chicago Medical Center, NYU Langone Health, New York University, University Medical Center Groningen, University of Groningen, University of Utah, Concord Repatriation General Hospital, University of British Columbia, The University of Sydney, The George Institute for Global Health, Imperial College London, University College London, Peking University First Hospital, Mount Sinai Hospital, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Stanford Medicine, Stanford University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Celgene, University of Chicago, University of Washington, Regeneron Pharmaceuticals, Ironwood Pharmaceuticals, Incorporated, Ablynx, MyoKardia, Verily Life Sciences, NxStage, Kidney Foundation of Canada, Novo Nordisk, Astellas Pharma, Servier, Akebia Therapeutics, National Institutes of Health, University of California, San Francisco, Canadian Institutes of Health Research, Medical Research Council, National Health and Medical Research Council, Relypsa, National Institute of Diabetes and Digestive and Kidney Diseases, Janssen Pharmaceuticals, Daiichi Sankyo Europe, Medical Research Future Fund
OpenAlex ID: W3005959108